Study of EYE103 for wet AMD or macular edema after BRVO
Treatments studied
Part of Eyes & vision, Heart & circulation clinical trials.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to understand the study and give written consent.
- For wet AMD: you must be 50 or older with a new diagnosis (within 21 days) of the condition in the study eye, or if you've had treatment before, your diagnosis must be within the last 90 days.
- For BRVO: you must have vision loss from the condition, be new to treatment, and have macular edema diagnosed within the last 9 months.
- You cannot be pregnant or breastfeeding.
- You cannot have had cataract or glaucoma surgery in the study eye in the last 90 days.
- You cannot be taking drugs known to harm the retina, like hydroxychloroquine or amiodarone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Hear when a new Neovascular Age-Related Macular Degeneration (NVAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.